Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;23(3):924-930.
doi: 10.1007/s12311-023-01547-z. Epub 2023 Apr 5.

Consensus Recommendations for Clinical Outcome Assessments and Registry Development in Ataxias: Ataxia Global Initiative (AGI) Working Group Expert Guidance

Collaborators, Affiliations
Review

Consensus Recommendations for Clinical Outcome Assessments and Registry Development in Ataxias: Ataxia Global Initiative (AGI) Working Group Expert Guidance

Thomas Klockgether et al. Cerebellum. 2024 Jun.

Abstract

To accelerate and facilitate clinical trials, the Ataxia Global Initiative (AGI) was established as a worldwide research platform for trial readiness in ataxias. One of AGI's major goals is the harmonization and standardization of outcome assessments. Clinical outcome assessments (COAs) that describe or reflect how a patient feels or functions are indispensable for clinical trials, but similarly important for observational studies and in routine patient care. The AGI working group on COAs has defined a set of data including a graded catalog of COAs that are recommended as a standard for future assessment and sharing of clinical data and joint clinical studies. Two datasets were defined: a mandatory dataset (minimal dataset) that can ideally be obtained during a routine clinical consultation and a more demanding extended dataset that is useful for research purposes. In the future, the currently most widely used clinician-reported outcome measure (ClinRO) in ataxia, the scale for the assessment and rating of ataxia (SARA), should be developed into a generally accepted instrument that can be used in upcoming clinical trials. Furthermore, there is an urgent need (i) to obtain more data on ataxia-specific, patient-reported outcome measures (PROs), (ii) to demonstrate and optimize sensitivity to change of many COAs, and (iii) to establish methods and evidence of anchoring change in COAs in patient meaningfulness, e.g., by determining patient-derived minimally meaningful thresholds of change.

Keywords: Activities of daily living (ADL); Ataxia; Clinical outcome assessment (COA); Scale for the assessment and rating of ataxia (SARA); Standardization.

PubMed Disclaimer

Conflict of interest statement

T.Klockgether has received research support from the Bundesministerium für Bildung und Forschung (BMBF), the National Institutes of Health (NIH), and Servier, and consultancy honoraria from Biogen, Roche, UCB, and Vico Therapeutics.

M.Synofzik has received research support from Servier and consultancy honoraria from Janssen, Ionis, Orphazyme, Servier, and AviadoBio.

Similar articles

Cited by

References

    1. Klockgether T, Ashizawa T, Brais B, Chuang R, Durr A, Fogel B, et al. Paving the way toward meaningful trials in ataxias: an ataxia global initiative perspective. Mov Disord. 2022;37:1125–1130. doi: 10.1002/mds.29032. - DOI - PubMed
    1. Conklin JE, Lieberman JV, Barnes CA, Louis DZ. Disease staging: implications for hospital reimbursement and management. Health Care Financ Rev. 1984;Suppl:13–22. - PMC - PubMed
    1. Saute JA, Donis KC, Serrano-Munuera C, Genis D, Ramirez LT, Mazzetti P, et al. Ataxia rating scales–psychometric profiles, natural history and their application in clinical trials. Cerebellum. 2012;11:488–504. doi: 10.1007/s12311-011-0316-8. - DOI - PubMed
    1. Paap BK, Roeske S, Durr A, Schöls L, Ashizawa T, Boesch S, et al. Standardized assessment of hereditary ataxia patients in clinical studies. Mov Disord Clin Pract. 2016;3:230–240. doi: 10.1002/mdc3.12315. - DOI - PMC - PubMed
    1. Sarro L, Nanetti L, Castaldo A, Mariotti C. Monitoring disease progression in spinocerebellar ataxias: implications for treatment and clinical research. Expert Rev Neurother. 2017;17:919–931. doi: 10.1080/14737175.2017.1364628. - DOI - PubMed

MeSH terms